Investors

Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.”

Press Releases

Click Here To Expand And Read

June 22, 2021

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

READ MORE

 

June 17, 2021

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership

READ MORE

 

June 16, 2021

Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.

READ MORE

 

June 10, 2021

Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

READ MORE

 

May 18, 2021

Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group

READ MORE

 

May 11, 2021

Entheon Biomedical Corp. Announces Participation in the Q2 Virtual Investor Summit

READ MORE

 

May 5, 2021

Entheon Biomedical Lists on OTCQB Venture Market

READ MORE

 

April 6, 2021

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

READ MORE

 

 

March 3, 2021

Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

READ MORE

 

FEBRUARY 24, 2021

Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences

READ MORE

 

FEBRUARY 22, 2021

Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study

READ MORE

 

FEBRUARY 16, 2021

Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

READ MORE

 

FEBRUARY 2, 2021

Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments

READ MORE

 

JANUARY 22, 2021

Entheon Biomedical to be Included in First North American Psychedelic ETF

READ MORE

 

JANUARY 19, 2021

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

READ MORE

 

JANUARY 14, 2021

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

READ MORE

 

JANUARY 12, 2021

Entheon Biomedical Engages Star Finance GmbH for Investor Relations

READ MORE

 

JANUARY 11, 2021

Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor

READ MORE

 

JANUARY 04, 2021

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

READ MORE

 

DECEMBER 25, 2020

Entheon Biomedical Closes Private Placement

READ MORE

 

DECEMBER 18, 2020

Entheon Biomedical Announces Private Placement

READ MORE

 

 

DECEMBER 09, 2020

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

READ MORE

 

 

DECEMBER 04, 2020

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

READ MORE

.

DECEMBER 01, 2020

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

READ MORE

.

NOVEMBER 12, 2020

Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange

READ MORE

.

NOVEMBER 05, 2020

Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange

READ MORE

.

OCTOBER 28, 2020

MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp.

READ MORE

.

MAY 07, 2020

Entheon Biomedical Announces Private Placement to Begin Pre-clinical Trials with Psychedelic Compounds DMT & 5 MEO DMT

READ MORE

.

Share Structure

Outstanding Shares

Fully Diluted

Outstanding Shares

Fully Diluted

Stock Information

🇨🇦  CSE: ENBI

🇺🇸  OTCQB: ENTBF

🇩🇪  FSE: 1XU1

🇨🇦  CSE: ENBI | 🇺🇸  OTCQB: ENTBF | 🇩🇪  FSE: 1XU1

Entheon News

When Will Psychedelics be Legal in the United States?

When Will Psychedelics be Legal in the United States?

With all eyes on the American election, we are sure that those in the psychedelic medicine sphere wonder what this could mean for the future of psychedelic medicine in the United States. Here’s our stance.